<DOC>
	<DOCNO>NCT01929889</DOCNO>
	<brief_summary>The study look whether treatment iloperidone ( Fanapt ) associate improvement social cognition individual recently diagnose schizophrenia schizoaffective disorder . Social cognition ( ability understand feeling feeling others ) closely related functional outcome , include communication , empathy , emotional recognition .</brief_summary>
	<brief_title>Assessing Effects Fanapt® Social Cognition Schizophrenia</brief_title>
	<detailed_description>Schizophrenia disable disease affect 1 % population one leading cause psychiatric disability . Striking early life , schizophrenia interferes work , relationship , independence . Despite billion dollar spend annually direct indirect cost disease , treatment option restore functionality . Lately , cognition emerge target intervention , since patient 's cognitive status one reliable predictor functional outcome , yet treatment improve cognition deliver modest result . This study attempt evaluate efficacy Fanapt® ( iloperidone ) social cognition , consist factor empathy , social perception , emotional recognition , may meaningfully tie functional outcome cognition general . This study assess social cognition people schizophrenia schizoaffective disorder newly begin take Fanapt® ( iloperidone ) , new antipsychotic mixed dopamine serotonin antagonism . Standard measure psychopathology social cognition collect baseline 12 week become stable medication , raters blind length subject 's participation study . We predict social cognition improve treatment Fanapt® . This study relatively risk , include risk beyond exposure study medication collection safety data psychometric data . The potential benefit outweigh risk , main benefit ability describe improvement cognitive performance believe relate directly real-world functional outcome .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Ability give write informed consent Male female patient 1855 year old DSMIVTR diagnosis schizophrenia schizoaffective disorder . Less 5year treatment history schizophrenia schizoaffective disorder . Clinically stable last 2 week Fanapt® screen stabilization phase . Sufficiently stable overall health . Women become pregnant must use adequate method contraception avoid pregnancy throughout study 4 week study People unable give inform consent Baseline performance 95 % high cognitive empathy assessment Pregnant lactate woman A positive test Hepatitis C antibody concurrent evidence impair hepatic function Subjects history medical condition would pose risk patient participate study might confound result study Known hypersensitivity Fanapt® component formulation History organic brain disorder History autism , pervasive developmental disability , mental retardation , cognitive disorder could potentially confound cognitive test History medical condition would confound presentation treatment schizophrenia schizoaffective disorder , significantly increase risk associate propose treatment protocol History QTc prolongation , cardiac arrhythmia , family history sudden cardiac death Patients take strong inhibitor CYP2D6 ( fluoxetine , paroxetine , etc . ) CYP3A4 ( ketoconazole , itraconazole , cimetidine , cyclosporine , etc . ) medication interact significantly iloperidone Patients meet DSMIVTR criterion current alcohol substance dependence within last six month DSMIVTR criterion alcohol substance abuse within last month Patients regularly take medication know interfere performance cognitive social cognitive task , anticholinergic benzodiazepine . Occasional benzodiazepine use may permit subject safely refrain use least 24 hour prior study visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>iloperidone</keyword>
	<keyword>Fanapt</keyword>
	<keyword>social cognition</keyword>
	<keyword>cognition</keyword>
</DOC>